Boundless Bio, Inc. (BOLD) — Annual Report

Key Insights

• The filing indicates Boundless Bio, Inc. (BOLD) has experienced growth in its research and development expenses over the past two fiscal years, which could signal increased investment in its product pipeline.
• Boundless Bio has a significant amount of cash, cash equivalents, and short-term investments on its balance sheet as of the end of the latest fiscal year, suggesting a strong liquidity position.
• The company has an open market sale agreement in place, which could provide additional funding if utilized, but also represents a potential dilution risk for shareholders.